Human immunodeficiency virus-related retinal microangiopathy and systemic cytomegalovirus disease association
- First Online:
To determine whether there is a significant association between human immunodeficiency virus (HIV)-related retinal microangiopathy and systemic cytomegalovirus (CMV) disease in HIV-infected patients.
Participants in this single-center, cross-sectional, retrospective study were 383 HIV-infected patients assessed for ocular manifestations before the beginning of antiretroviral therapy. The presence of HIV-related retinal microangiopathy, the presence of systemic CMV disease, laboratory data, and demographic information were determined by referring to medical records. The significance of any association between HIV-related retinal microangiopathy and systemic CMV disease was determined by use of the Chi-squared test and by multivariate analysis.
HIV-related retinal microangiopathy was present in 85 patients, and was significantly associated with systemic CMV disease both by use of the Chi-squared test (P = 0.006) and by multivariate analysis (P = 0.045, odds ratio 2.03, 95 % confidence interval 1.02–4.06 adjusted for CD4+ cell count and plasma HIV-RNA level).
These findings indicate that microangiopathy may be involved in the development of CMV disease in HIV-infected patients. Thus, detection of the presence of HIV-related retinal microangiopathy is important in the management of HIV-infected patients.
KeywordsMicroangiopathy Cotton-wool spots Cytomegalovirus Human immunodeficiency virus Acquired immune deficiency syndrome
- 1.Jabs DA, Quinn TC. Acquired immunodeficiency syndrome. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. 1st ed. St. Louis, MO: Mosby-Year Book Inc.; 1996. p. 289–310.Google Scholar
- 10.Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV Infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recomm Rep. 2008;57:1–12.PubMedGoogle Scholar
- 11.Holland GN, Tufail A, Jordan MC. Cytomegalovirus Disease. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. 1st ed. St. Louis, MO: Mosby-Year Book Inc.; 1996. p. 1088–128.Google Scholar
- 17.Mofenson LM, Harris DR, Rich K, Meyer WA 3rd, Read JS, Moye J Jr, et al. Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. AIDS. 1999;13:31–9.PubMedCrossRefGoogle Scholar
- 27.Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C, Collaborations in HIV Outcomes Research/US Cohort, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004;39(Suppl5):S267–75.PubMedCrossRefGoogle Scholar
- 30.Kuppermann BD, Petty JG, Richman DD, Mathews WC, Fullerton SC, Rickman LS, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575–82.PubMedGoogle Scholar
- 31.Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, AIDS Clinical Trials Group Protocol 360 Study Team, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis. 2003;37:567–78.PubMedCrossRefGoogle Scholar